The team at eyeforphama brings us a new whitepaper which analyzes how Big Pharma must adapt its stakeholder engagement strategy to reflect the new landscape created by the emergence of the ACO. This paper provides insights from Aetna, Orange Health, Eli Lilly, the Association of Community Cancer Centers, Arizona Care Network and Independent Physician’s ACO of Chicago. You may access the free paper here. (Source: eyeforpharma, 11/11/2013)
You are here: / / Do Lilly, Aetna and More Understand ACO Engagement for Specialty Rx?